Stakeholders warn of over-reliance on Chinese APIs

Multiple speakers at a hearing on U.S. use of China biotech supplies this week warned that relying on the country's supplies and services threatens the U.S. drug supply, consumer safety and personal health data.

“The national security risks of increased Chinese dominance of the global API market cannot be overstated,” Christopher Priest, deputy director of health operations at the Defence Health Agency, said in prepared remarks at the hearing of the U.S.-China Economic and Security Review Commission...